COL18A1 and small cell lung carcinoma: Other antiangiogenic agents, including antibodies (ziv-aflibercept) and small molecules agents (rh-endostatin, vandetanib, sunitinib, sorafenib, cediranib, nintedanib, thalidomide, and anlotinib) have been tested in SCLC (Table 2).